MedTrace Logo

Vaccination of Patients With Stage IV Melanoma With Dendritic Cells

NCT00125749 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-06-12

No results posted yet for this study

Summary

The purpose of this study is to test a novel dendritic cell (DC) vaccine in patients with Stage IV melanoma.

Conditions

Interventions

BIOLOGICAL

Dendritic cell vaccination

Autologous Dendritic Cells Derived from PBMC, Cultured with Cytokines, Pulsed Ex Vivo with Irradiated Allogeneic (Colo 829) Melanoma Cells

Sponsors & Collaborators

  • Mary Crowley Medical Research Center

    collaborator OTHER

  • ODC Therapy

    collaborator UNKNOWN

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • Anna Karolina Palucka, MD, PhD · Baylor Institute for Immunology Research: Baylor University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125749 on ClinicalTrials.gov